Article
Practical management of myelofibrosis with ruxolitinib.
Internal medicine journal - 1 Dec 2015
Ho P J, Marlton P, Tam C, Stevenson W, Ritchie D, Bird R, Dunlop L C, Durrant S, Ross D M
Abstract excerpt
Treatment for the majority of patients with myelofibrosis is primarily based on symptom control as curative allogeneic stem cell transplantation is typically offered only to younger patients, especially those with poor prognosis disease. Around 50% of patients with myelofibrosis have the JAK2(V617F) mutation, but almost all patients have aberrant activation of the JAK-STAT signalling pathway. Recent efforts have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.